Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy

Progeria Clinical Trial

Official title:
A Treatment IND (Investigational New Drug) Protocol for EAP (Expanded Access Program) for the Use of Lonafarnib in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) or Progeroid Laminopathy

Status Approved for marketing

Clinical Trial Summary

This treatment IND protocol will allow patients with HGPS and progeroid laminopathies access to lonafarnib, the only compound shown to have an effect on the HGPS disease process resulting in improved outcomes (Gordon et al, 2018). There are no approved treatments for HGPS and progeroid laminopathies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03895528
Study type	Expanded Access
Source	Eiger BioPharmaceuticals
Contact
Status	Approved for marketing
Phase

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00094393` - Clinical Studies of Progeria
Completed	`NCT00425607` - Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria	Phase 2
Completed	`NCT00879034` - A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria	Phase 2
Enrolling by invitation	`NCT02579044` - Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria	Phase 1/Phase 2
Active, not recruiting	`NCT00916747` - Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria	Phase 2